JP5701216B2 - 加齢黄斑変性における遺伝的多型 - Google Patents

加齢黄斑変性における遺伝的多型 Download PDF

Info

Publication number
JP5701216B2
JP5701216B2 JP2011534924A JP2011534924A JP5701216B2 JP 5701216 B2 JP5701216 B2 JP 5701216B2 JP 2011534924 A JP2011534924 A JP 2011534924A JP 2011534924 A JP2011534924 A JP 2011534924A JP 5701216 B2 JP5701216 B2 JP 5701216B2
Authority
JP
Japan
Prior art keywords
oligonucleotide
allele
vegf antibody
gene
amd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011534924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507988A (ja
JP2012507988A5 (enExample
Inventor
ロバート アール． グレアム，
ロバート アール． グレアム，
ティモシー ダブリュ． ベーレンス，
ティモシー ダブリュ． ベーレンス，
ツォンチョ イアンシュレフ，
ツォンチョ イアンシュレフ，
， ハワード シャピロ
， ハワード シャピロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2012507988A publication Critical patent/JP2012507988A/ja
Publication of JP2012507988A5 publication Critical patent/JP2012507988A5/ja
Application granted granted Critical
Publication of JP5701216B2 publication Critical patent/JP5701216B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6846—Common amplification features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/137—Ligase Chain Reaction [LCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2011534924A 2008-11-05 2009-11-05 加齢黄斑変性における遺伝的多型 Expired - Fee Related JP5701216B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11166708P 2008-11-05 2008-11-05
US61/111,667 2008-11-05
US17485609P 2009-05-01 2009-05-01
US61/174,856 2009-05-01
PCT/US2009/063434 WO2010054110A2 (en) 2008-11-05 2009-11-05 Genetic polymorphisms in age-related macular degeneration

Publications (3)

Publication Number Publication Date
JP2012507988A JP2012507988A (ja) 2012-04-05
JP2012507988A5 JP2012507988A5 (enExample) 2014-09-18
JP5701216B2 true JP5701216B2 (ja) 2015-04-15

Family

ID=41650496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534924A Expired - Fee Related JP5701216B2 (ja) 2008-11-05 2009-11-05 加齢黄斑変性における遺伝的多型

Country Status (14)

Country Link
US (2) US20120003641A1 (enExample)
EP (2) EP2356250A2 (enExample)
JP (1) JP5701216B2 (enExample)
KR (1) KR101719376B1 (enExample)
CN (2) CN103333952B (enExample)
AU (1) AU2009313475B2 (enExample)
CA (1) CA2740242A1 (enExample)
DK (1) DK2540843T3 (enExample)
ES (1) ES2498274T3 (enExample)
IL (1) IL211995A (enExample)
MX (1) MX2011004763A (enExample)
PL (1) PL2540843T3 (enExample)
SI (1) SI2540843T1 (enExample)
WO (1) WO2010054110A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
RU2486253C2 (ru) 2008-07-25 2013-06-27 Инфоком Корпорейшн Онкоген nrf2 и его применение
AR085301A1 (es) * 2011-02-23 2013-09-18 Sanofi Sa Polimorfismos de un solo nucleotido en el promotor del gen vegfa y su uso como marcadores predictivos para tratamientos anti-vegf
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN110564819A (zh) 2011-05-19 2019-12-13 基纳生物技术有限公司 用于多重核酸鉴定的产品和方法
WO2013030032A1 (en) * 2011-08-26 2013-03-07 F. Hoffmann-La Roche Ag A method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders
MX390891B (es) * 2011-10-14 2025-03-19 Genentech Inc ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO.
US20140004105A1 (en) * 2012-06-29 2014-01-02 Sequenom, Inc. Age-related macular degeneration diagnostics
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016008975A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
EP3233115B1 (en) * 2014-12-19 2021-02-17 Children's Hospital Medical Center Methods and compositions related to transplant-associated thrombotic microangiopathy
JP2018512880A (ja) 2015-04-24 2018-05-24 アジーナ バイオサイエンス， インコーポレイテッド 少量の対立遺伝子および多型の同定ならびに定量のためのマルチプレックス法
CN104878105B (zh) * 2015-06-02 2017-10-31 北京医院 一种预测雷珠单抗治疗年龄相关性黄斑变性疗效的试剂
CN104894261B (zh) * 2015-06-02 2020-02-14 北京医院 一种预测雷珠单抗治疗年龄相关性黄斑变性疗效的试剂盒
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017148904A1 (en) * 2016-02-29 2017-09-08 Franz Grus Predictive markers useful in the treatment of wet age-related macular degeneration
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
EP4257191A3 (en) 2016-06-21 2023-11-22 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113373236B (zh) * 2021-02-19 2021-12-31 中国科学院北京基因组研究所(国家生物信息中心) 一种获得中国人群个体年龄的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
AU9381598A (en) 1997-09-10 1999-03-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of amplifying dna and rna mismatch cleavage products
AU2005314461B2 (en) * 2004-11-18 2012-02-02 The Rockefeller University Methods and compositions for treating ocular disorders
WO2008103299A2 (en) * 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration

Also Published As

Publication number Publication date
CA2740242A1 (en) 2010-05-14
KR20110081836A (ko) 2011-07-14
EP2540843A3 (en) 2013-05-29
US20170159114A1 (en) 2017-06-08
MX2011004763A (es) 2011-06-01
WO2010054110A2 (en) 2010-05-14
EP2540843B1 (en) 2014-07-02
HK1173751A1 (en) 2013-05-24
EP2540843A2 (en) 2013-01-02
BRPI0914368A2 (pt) 2015-10-20
ES2498274T3 (es) 2014-09-24
JP2012507988A (ja) 2012-04-05
IL211995A0 (en) 2011-06-30
DK2540843T3 (da) 2014-09-01
IL211995A (en) 2014-04-30
PL2540843T3 (pl) 2014-12-31
CN102203296A (zh) 2011-09-28
CN103333952B (zh) 2015-07-29
US20120003641A1 (en) 2012-01-05
AU2009313475A1 (en) 2010-05-14
EP2356250A2 (en) 2011-08-17
CN102203296B (zh) 2014-12-03
KR101719376B1 (ko) 2017-03-23
SI2540843T1 (sl) 2014-10-30
WO2010054110A3 (en) 2010-08-19
CN103333952A (zh) 2013-10-02
AU2009313475B2 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
AU2009313475B2 (en) Genetic polymorphisms in age-related macular degeneration
JP5676623B2 (ja) 加齢黄斑変性における遺伝的多型性
KR20100020960A (ko) 자궁내막증과 연관된 유전자 마커 및 이의 용도
US20110177969A1 (en) The role of il17rd and the il23-1l17 pathway in crohn's disease
WO2006017854A2 (en) Compositions and methods for determining and predicting treatment responses for depression and anxiety
CA3174572A1 (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
WO2015168252A1 (en) Mitochondrial dna copy number as a predictor of frailty, cardiovascular disease, diabetes, and all-cause mortality
HK1173751B (en) Genetic polymorphisms in age-related macular degeneration
BRPI0914368B1 (pt) Método para predizer se um paciente com degeneração macular relacionada à idade (dmri) úmida tem uma maior probabilidade de se beneficiar pelo tratamento com um anticorpo anti-vegf e método para predizer se um indivíduo tem uma maior probabilidade de desenvolver dmri úmida ou dmri seca com atrofia geográfica (ag)
HK1173192B (en) Genetic polymorphisms in age-related macular degeneration
HK1173192A (en) Genetic polymorphisms in age-related macular degeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140430

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150217

R150 Certificate of patent or registration of utility model

Ref document number: 5701216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees